Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors

A. P. Rapoport*, R. Lifton, L. S. Constine, R. E. Duerst, C. N. Abboud, J. L. Liesveld, C. H. Packman, S. Eberly, R. F. Raubertas, B. A. Martin, W. R. Flesher, P. A. Kouides, J. F. Dipersio, J. M. Rowe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years (range 0-7.5 years). For patients entering with minimal disease (defined as all areas ≤ 2 cm), the 5-year EFS was 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on entry and administration of involved-held XRT post-transplant were significantly associated with improved EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to reduce the high rate of relapse (50-60%) following autotransplantation for relapsed or refractory NHL.

Original languageEnglish (US)
Pages (from-to)883-890
Number of pages8
JournalBone Marrow Transplantation
Volume19
Issue number9
DOIs
StatePublished - May 1 1997

Keywords

  • Autotransplantation
  • Lymphoma
  • Prognostic factors
  • Radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors'. Together they form a unique fingerprint.

Cite this